Menu
Search Close

News

Change of Registered Office

13th April 2017

Scancell Holdings Plc

("Scancell" or the "Company")

Change of Registered Office

Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, announces that it has changed its registered office address.

The new registered office address for Scancell is:

John Eccles House

Robert Robinson Avenue

Oxford Science Park

Oxford OX4 4GP

 

For Further Information:

Scancell Holdings Plc

Dr John Chiplin, Executive Chairman

Dr Richard Goodfellow, CEO

Scancell Holdings Plc

 

+1 858 900 2646

+44 (0) 20 3727 1000

 

 

 

 

 

Freddy Crossley (Corporate Finance)

Tom Salvesen (Corporate Broking)

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

+44 (0) 20 7886 2500

 

 

 

 

Mo Noonan/Simon Conway

FTI Consulting

+44 (0) 20 3727 1000

 

 

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma.  Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.  In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence. 

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells. 

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.  Experimental data suggests that the high avidity T cells induced by ImmunoBody® vaccines increase expression of PDL-1 on the tumour cell surface, thereby making the tumours more sensitive to checkpoint inhibitor drugs.  Re-challenging animals with tumour cells after SCIB1 treatment resulted in 100% survival suggesting that ImmunoBody® induces a powerful memory response.  Such an effect has not been observed with checkpoint inhibitors. 

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity.  The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Webcasts, Interviews and Media Coverage

Scancell on verge of recruiting patients with advanced melanoma for UK clinical trials

The immunotherapy specialist gave an update on progress for a “busy and productive” half-year.

Mon, 01 Jul 2019 11:19:00